Pharmaceutical sponsor
Inmunotek S.L. Clinical Trials
Studies where Inmunotek S.L. is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 11Allergic Rhinitis, Allergic Rhinoconjunctivitis
Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063.
The goal of this clinical trial is to learn whether EP-088_MM09 works to treat house dust mite allergy. It will also assess the treatment's safety.
- Conditions
- Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma
- Trial name
- MM09-SIT-063 (NCT07904052)
- Testing
- EP-088_MM09
- Where
- 16 sites in Portugal, Spain
- Volunteers
- 250 people
- Sponsor
- Inmunotek S.L.
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-063.
The goal of this clinical trial is to learn whether EP-088_MM09 works to treat house dust mite allergy. It will also assess the treatment's safety.
- Conditions
- Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma
- Trial name
- NCT07904195
- Testing
- EP-088_MM09
- Where
- 16 sites in Portugal, Spain
- Volunteers
- 250 people
- Sponsor
- Inmunotek S.L.
Rhinitis, Rhinoconjunctivitis
Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df
The goal of this clinical trial is to learn if MM09 works to treat patients allergic to house mites, displaying rhinitis/rhinoconjunctivitis with or without mild to moderate asthma. It will also learn about the safety of MM09.
- Trial name
- Oraltek-58 (NCT07348302)
- Testing
- Allergen Immunotherapy Extract
- Where
- 19 sites in Argentina, China and 2 more
- Volunteers
- 736 people
- Sponsor
- Inmunotek S.L.
Allergic Reactions, Allergic Skin Reaction
Determination of Blomia Tropicalis Allergen Extract in Prick Test Units
The primary objective is to assess the concentration of Blomia tropicalis allergenic extract that induces a wheal of size equivalent to that produced by a 10 mg/mL histamine dihydrochloride solution, in order to be used as…
- Trial name
- NCT07195929
- Testing
- Allergenic Extract
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Inmunotek S.L.
Rhinitis, Allergic, Rhinoconjunctivitis
Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.
A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy in Patients With Rhinitis/Rhinoconjunctivitis With or Without Mild to…
- Conditions
- Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
- Trial name
- NCT04898283
- Testing
- 10,000 MG01 +10,000 T521, 30,000 MG01 +10,000 T521
- Where
- 27 sites in Spain
- Volunteers
- 180 people
- Sponsor
- Inmunotek S.L.
Rhinitis, Allergic, Rhinoconjunctivitis
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
A double-blinded, placebo-controlled, prospective, multicenter randomized of 2 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with…
- Conditions
- Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
- Trial name
- MM09-SIT-023 (NCT04435990)
- Testing
- 10,000 MM09, 30,000 MM09
- Where
- 32 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Inmunotek S.L.
Rhinitis, Allergic, Rhinoconjunctivitis
Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen
Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis / rhinoconjunctivitis with or without mild to…
- Conditions
- Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
- Trial name
- NCT04891237
- Testing
- 10,000 MG01 + 10,000 T517, 30,000 MG01 + 10,000 T517
- Where
- 32 sites in Spain
- Volunteers
- 180 people
- Sponsor
- Inmunotek S.L.
Allergy, Insect Venom, Allergy Insect Stinging
Prospective Observational Study to Evaluate the Safety of Immunotherapy as a Treatment for Hymenoptera Venom Allergy
Observational study to evaluate the safety of immunotherapy as a treatment for Hymenoptera venom allergy, analyzing the adverse reaction to immunotherapy as well as the allergic reaction to a spontaneous hymenoptera sting.
- Conditions
- Allergy, Insect Venom, Allergy Insect Stinging, Insect Sting Allergy
- Trial name
- NCT06782217
- Testing
- VENOX
- Where
- 9 sites in Spain
- Volunteers
- 120 people
- Sponsor
- Inmunotek S.L.
Allergic Reaction, Allergic Skin Reaction
Quercus Ilex and Quercus Robur Allergen Extracts Standardisation
The objective of this study is to determine the biological activity of Quercus illex and Quercus robur allergen extracts in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
- Conditions
- Allergic Reaction, Allergic Skin Reaction, Allergy Pollen
- Trial name
- NCT05532566
- Testing
- Allergenic extract
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Inmunotek S.L.
Allergy, Insect Venom, Allergy Insect Stinging
Immunotherapy for the Treatment of Hymenoptera Venom Allergy in Real-life Conditions.
Observational clinical follow-up to evaluate the safety of immunotherapy for the treatment of hymenoptera venom allergy in real-life conditions. It includes the evaluation of controlled and spontaneous stings.
- Conditions
- Allergy, Insect Venom, Allergy Insect Stinging, Insect Sting Allergy
- Trial name
- Venox-23 (NCT06790368)
- Testing
- VENOX
- Where
- 3 sites in Spain
- Volunteers
- 80 people
- Sponsor
- Inmunotek S.L.
Completed, with results posted
All 3Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)
The goal of this clinical trial is to learn whether the bacterial vaccine MV130 helps reduce the number of exacerbations in adults with moderate to severe COPD. It will also assess the safety and immune effects of MV130.
- Trial name
- MV130 (NCT01842360)
- Testing
- MV130
- Where
- 7 sites in Spain
- Volunteers
- 198 people
- Sponsor
- Inmunotek S.L.
Immune System Diseases
Determination of the Sensitivity and Specificity of Prick Test Betula Verrucosa
The main objective is to evaluate the concentration of allergen extract of Betula verrucosa that elicit a papule equivalent to that produced by a solution of histamine dihydrochloride 10 mg / ml in size.
- Trial name
- T502 (NCT02527187)
- Testing
- 10 HEP/mL Betula verrucosa allergen extract, 25 HEP/mL Betula verrucosa allergen extract, 50 HEP/mL Betula verrucosa allergen extract
- Where
- Spain
- Volunteers
- 201 people
- Sponsor
- Inmunotek S.L.
Bronchospasm; Bronchiolitis, Bronchospasm; Bronchitis
Efficacy and Safety Evaluation in Recurrent Wheezing Attacks
The study will be conducted in two hospitals of the same geographic area. It will be included children <3-years-old with recurrent wheezing attacks, confirmed by the review of the medical records, in the previous 12 months or a…
- Trial name
- MV130 (NCT01734811)
- Testing
- Biological vaccine
- Where
- 2 sites in Spain
- Volunteers
- 120 people
- Sponsor
- Inmunotek S.L.